There are high number of clear evidence that breastfeeding provides best nutrition that you can give to your baby. It is also evident that lactation is good for mothers health as well. Evolution has designed breastfeeding in a way that it caters all nutritional need of your child. However modern medicine is quite new for evolution, that is why mothers body is not well prepared to filter unnecessary chemical found in medicines. It becomes a necessity to figure out which drug is safe and which drug is dangerous for your newborn while nursing. In this article we will understand function of Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg and its suitability with breastfeeding.
What is Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg used for?
AVALIDE® (irbesartan-hydrochlorothiazide) Tablets is indicated for the treatment of hypertension. AVALIDE may be used in patients whose blood pressure is not adequately controlled on monotherapy. AVALIDE may also be used as initial therapy in patients who are likely to need multiple drugs to achieve their blood pressure goals. The choice of AVALIDE as initial therapy for hypertension should be based on an assessment of potential benefits and risks. Patients with stage 2 (moderate or severe) hypertension are at relatively high risk for cardiovascular events (such as strokes, heart attacks, and heart failure), kidney failure, and vision problems, so prompt treatment is clinically relevant. The decision to use a combination as initial therapy should be individualized and may be shaped by considerations such as the baseline blood pressure, the target goal, and the incremental likelihood of achieving goal with a combination compared with monotherapy. Data from Studies V and VI [see Clinical Studies (14.2) ] provide estimates of the probability of reaching a blood pressure goal with AVALIDE compared to irbesartan or HCTZ monotherapy. The relationship between baseline blood pressure and achievement of a SeSBP less than 140 or less than 130 mmHg or SeDBP less than 90 or less than 80 mmHg in patients treated with AVALIDE compared to patients treated with irbesartan or HCTZ monotherapy are shown in Figures 1a through 2b. Figure 1a: Probability of Achieving SBP Less Than 140 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 1b: Probability of Achieving SBP Less Than 130 mmHg in Patientsfrom Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2a: Probability of Achieving DBP Less Than 90 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* Figure 2b: Probability of Achieving DBP Less Than 80 mmHg in Patients from Initial Therapy Studies V (Week 8) and VI (Week 7)* *For all probability curves, patients without blood pressure measurements at Week 7 (Study VI) and Week 8 (Study V) were counted as not reaching goal (intent-to-treat analysis). The above graphs provide a rough approximation of the likelihood of reaching a targeted blood pressure goal (eg, Week 8 sitting systolic blood pressure less than or equal to 140 mmHg) for the treatment groups. The curve of each treatment group in each study was estimated by logistic regression modeling from all available data of that treatment group. The estimated likelihood at the right tail of each curve is less reliable due to small numbers of subjects with high baseline blood pressures. For example, a patient with a blood pressure of 180/105 mmHg has about a 25% likelihood of achieving a goal of less than 140 mmHg (systolic) and 50% likelihood of achieving less than 90 mmHg (diastolic) on irbesartan alone (and lower still likelihoods on HCTZ alone). The likelihood of achieving these goals on AVALIDE rises to about 40% (systolic) or 70% (diastolic). image of Figure 1a: Probability of Achieving SBP graph image of Figure 1b: Probability of Achieving SBP graph image of Figure 2a: Probability of Achieving DBP graph image of Figure 2b: Probability of Achieving DBP graph
Is Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg safe to use while breastfeeding? Can it interfere with growth and development of my kid?
Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg consists two active ingredients Irbesartan and Hydrochlorothiazide and as per our analysis of both we have determined the Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg is unsafe during breastfeeding. We recommend you to check both ingredients below for better understanding of Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg in breastfeeding.
Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg Breastfeeding Analsys
Irbesartan while Breastfeeding Unsafe
CAS Number: 138402-11-6
At latest update, relevant published data on excretion into breast milk were not found. Because of a high protein-binding capacity, a significant excretion into breast milk is unlikely. However, it is one among the Sartan drugs (ARA-II type) with the longest half-life and highest oral bioavailability. The latter properties make it less convenient for use while breastfeeding. Reportedly, a newborn infant appeared with transient renal failure (kidney malfunction) whose mother had taken this medication during pregnancy. Until more data on this medication is available safer alternative drugs are preferred especially in premature babies or during the neonatal period. Should an ARA-II medication (Sartan type) be necessary, the associated risk may be decreased by choosing the one with a favorable pharmacokinetics (shorter half-life elimination time and lower bioavailability) like Eprosartan and Losartan.
Hydrochlorothiazide while Breastfeeding Safe
CAS Number: 58-93-5
Thiazide diuretic drug. Excretion into breast milk is clinically non-significant. No side-effects were observed in a one-month old breastfed baby whose mother was treated with this medication. Drug level in the plasma of this child was undetectable. Long-term treatment with diuretic drugs (particularly Thiazide type ones with long-lasting effect and loop-acting mechanism) may inhibit lactation, mostly if lactation is not well-established yet. Use as lower dose as possible, especially during the first postnatal month. American Academy of Pediatrics 2013: Maternal Medication Usually Compatible With Breastfeeding. WHO Model List of Essential Drugs 2002: Compatible with breastfeeding.
Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg Breastfeeding Analsys - 2
Irbesartan while Breastfeeding
CAS Number: 138402-11-6
Because no information is available on the use of irbesartan during breastfeeding, an alternate drug may be preferred, especially while nursing a newborn or preterm infant.
Hydrochlorothiazide while Breastfeeding
CAS Number: 58-93-5
Hydrochlorothiazide doses of 50 mg daily or less are acceptable during lactation. Intense diuresis with large doses may decrease breastmilk production.
What should I do if I am breastfeeding mother and I am already exposed to Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg?
If you observer abnormal behavior or any other health issue in infant then you should immediately call 911 or contact other contact other emergency service provider in your area otherwise closely monitor the baby and inform your doctor about your Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg usage and time interval of breastfeeding.
My health care provider has asked me to use Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg, what to do?
If your doctor knows that you are breastfeeding mother and still prescribes Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg then there must be good reason for that as Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg is considered unsafe, It usually happens when doctor finds that overall advantage of taking outweighs the overall risk.
If I am using Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg, will my baby need extra monitoring?
Yes, Extra monitoring is required if mother is using Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg and breastfeeding as it is considered unsafe for baby.
Who can I talk to if I have questions about usage of Avalide | Irbesartan 0.5 Mg, Hydrochlorothiazide 0.5 Mg in breastfeeding?
National Womens Health and Breastfeeding Helpline: 800-994-9662 (TDD 888-220-5446) 9 a.m. and 6 p.m. ET, Monday through Friday
National Breastfeeding Helpline: 0300-100-0212 9.30am to 9.30pm, daily
Association of Breastfeeding Mothers: 0300-330-5453
La Leche League: 0345-120-2918
The Breastfeeding Network supporter line in Bengali and Sylheti: 0300-456-2421
National Childbirth Trust (NCT): 0300-330-0700
National Breastfeeding Helpline: 1800-686-268 24 hours a day, 7 days a week
Telehealth Ontario for breastfeeding: 1-866-797-0000 24 hours a day, 7 days a week